Seeking Alpha

Endocyte falls as vintafolide monotherapy unlikely to show NSCLC PFS superiority

Endocyte (ECYT) plummets as the DSMB for TARGET advises investigators and patients that vintafolide monotherapy is not likely to be declared superior in PFS to docetaxel.

The Phase 2b trial had two arms, vintafolide monotherapy and vintafolide in combination with docetaxel, which were to be compared with standard of care (docetaxel monotherapy).

The DSMB did recommend the continuation of the combination therapy arm.

Top-line results are due early next year. (PR)

ECYT -27.4% premarket

Comments (3)
  • TruffelPig
    , contributor
    Comments (4081) | Send Message
    27% when they continue one arm? I think this is too much.
    11 Oct 2013, 08:29 AM Reply Like
  • TruffelPig
    , contributor
    Comments (4081) | Send Message
    Read the release - ECYT is happy with the Tax/Vintafolide arm. This is bad news and good news I say.
    11 Oct 2013, 08:34 AM Reply Like
  • TruffelPig
    , contributor
    Comments (4081) | Send Message
    Also to SA: the PM thus far had 2000 shares traded, lol. That is not exactly liquidity.
    11 Oct 2013, 08:40 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs